Book contents
- Frontmatter
- Contents
- List of contributors
- Preface
- Part I Introduction: definition and classification of the human herpesviruses
- Part II Basic virology and viral gene effects on host cell functions: alphaherpesviruses
- Part II Basic virology and viral gene effects on host cell functions: betaherpesviruses
- Part II Basic virology and viral gene effects on host cell functions: gammaherpesviruses
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HSV-1 and HSV-2
- Part III Pathogenesis, clinical disease, host response, and epidemiology: VZU
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HCMV
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HHV- 6A, 6B, and 7
- Part III Pathogenesis, clinical disease, host response, and epidemiology: gammaherpesviruses
- Part IV Non-human primate herpesviruses
- Part V Subversion of adaptive immunity
- Part VI Antiviral therapy
- Part VII Vaccines and immunothgerapy
- 69 Herpes simplex vaccines
- 70 Varicella-zoster vaccine
- 71 Human cytomegalovirus vaccines
- 72 Epstein–Barr virus vaccines
- 73 DNA vaccines for humanherpesviruses
- 74 Adoptive immunotherapy for herpesviruses
- 75 Immunotherapy of HSV infections – antibody delivery
- Part VIII Herpes as therapeutic agents
- Index
- Plate section
- References
71 - Human cytomegalovirus vaccines
from Part VII - Vaccines and immunothgerapy
Published online by Cambridge University Press: 24 December 2009
- Frontmatter
- Contents
- List of contributors
- Preface
- Part I Introduction: definition and classification of the human herpesviruses
- Part II Basic virology and viral gene effects on host cell functions: alphaherpesviruses
- Part II Basic virology and viral gene effects on host cell functions: betaherpesviruses
- Part II Basic virology and viral gene effects on host cell functions: gammaherpesviruses
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HSV-1 and HSV-2
- Part III Pathogenesis, clinical disease, host response, and epidemiology: VZU
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HCMV
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HHV- 6A, 6B, and 7
- Part III Pathogenesis, clinical disease, host response, and epidemiology: gammaherpesviruses
- Part IV Non-human primate herpesviruses
- Part V Subversion of adaptive immunity
- Part VI Antiviral therapy
- Part VII Vaccines and immunothgerapy
- 69 Herpes simplex vaccines
- 70 Varicella-zoster vaccine
- 71 Human cytomegalovirus vaccines
- 72 Epstein–Barr virus vaccines
- 73 DNA vaccines for humanherpesviruses
- 74 Adoptive immunotherapy for herpesviruses
- 75 Immunotherapy of HSV infections – antibody delivery
- Part VIII Herpes as therapeutic agents
- Index
- Plate section
- References
Summary
Efforts to develop a human cytomegalovirus (HCMV) vaccine began more than 30 years ago in response to then recent reports that HCMV was capable of causing severe congenital disease. During the intervening years, our understanding of HCMV biology and immunology has increased dramatically. That knowledge, coupled with the introduction of several new vaccine methodologies, opened the door to an impressive expansion of HCMV vaccine research, particularly during the past decade. This chapter focuses on the principles underlying HCMV vaccine development and on the vaccine approaches that are currently under investigation.
Cytomegalovirus and human disease
The manifestations of HCMV infection vary with the age and immunocompetence of the host. In both adults and children, HCMV infection is usually asymptomatic. On rare occasions, otherwise healthy adults with primary HCMV infection will experience an infectious mononucleosis-like syndrome, with prolonged fever and mild hepatitis (Cohen and Corey, 1985). However, HCMV can cause serious morbidity and mortality when the host is unable to mount an adequate immune response or when infection is acquired in utero.
Congenital HCMV infection occurs in about 1% of children born in the USA, resulting in approximately 40 000 new infections each year (Pass and Burke, 2002; Plotkin, 1999). More than 90% of infected infants are asymptomatic at birth, and most will escape serious consequences of HCMV infection.
- Type
- Chapter
- Information
- Human HerpesvirusesBiology, Therapy, and Immunoprophylaxis, pp. 1274 - 1291Publisher: Cambridge University PressPrint publication year: 2007
References
- 4
- Cited by